The cardiovascular safety of triphasic contraceptive steroids.
It was hypothesized that estrogen-induced cardioprotection is mediated by up-regulation and down-regulation of expression of nitric oxide (NO) and P-selectin, respectively. Published data on circulating levels of the vasodilator NO, atherogenic glycoprotein P-selectin, and lipoprotein-a [Lp(a)] in users of triphasic contraceptive steroids are lacking. A total of 30 healthy women (nonusers, controls) and 82 women using oral triphasic contraceptive steroids (ethinyl estradiol and levonorgestrel: Triovlar, Schering AG) for 18 to 24 cycles participated in this study. Fasting blood samples were obtained from users and nonusers for the determination of P-selectin and Lp(a) by enzyme immunoassay and NO by a colorimetric method. The serum Lp(a) levels in OC users were significantly higher than those of nonusers. On the other hand, the serum NO levels in OC users were significantly elevated when compared to nonusers. Plasma P-selectin was significantly lowered in OC users p < 0.005. These results demonstrate the beneficial effects of ethinyl estradiol in the triphasic contraceptive regimen. Ethinyl estradiol may afford a degree of anti-atherogenic-cardioprotective effect by up-regulation of the expression of the vasodilator NO and down-regulation of the expression of the atherogenic P-selectin. This may outweigh the cardiovascular risk of the increased atherogenic Lp(a). This study may explain the very low rate of mortality from venous thromboembolism in OC users, which compares favorably with the risks that many people accept in daily life.
Shaarawy
M
M
Endocrinology and Maternal Biochemistry Unit, Faculty of Medicine, Cairo University, Egypt.
Nafea
S
S
Abdel-Aziz
O
O
Rahseed
K
K
Sheiba
M
M
D000328:Adult; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control*; D003276:Contraceptives, Oral / Q000494:pharmacology*; D045166:Estradiol Congeners / Q000008:administration & dosage / Q000494:pharmacology; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage / Q000494:pharmacology; D017270:Lipoprotein(a) / Q000097:blood; D009569:Nitric Oxide / Q000097:blood; D019007:P-Selectin / Q000097:blood; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000494:pharmacology
D003276:Contraceptives, Oral; D045166:Estradiol Congeners; D017270:Lipoprotein(a); D019007:P-Selectin; D045167:Progesterone Congeners; D009569:Nitric Oxide; D004997:Ethinyl Estradiol; D016912:Levonorgestrel